Patents Examined by Bruce R. Campbell
  • Patent number: 5770581
    Abstract: The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignees: Arch Development Corp., Dana-Farber Cancer Institute
    Inventors: Ralph R. Weichselbaum, Dennis E. Hallahan, Vikas P. Sukhatme, Donald W. Kufe
  • Patent number: 5759536
    Abstract: A method for inhibiting T-lymphocyte-mediated immune responses, including those directed against autologous and/or heterologous tissues, e.g., by a recipient mammal of a transplanted tissue, said method comprising providing the recipient mammal with Fas ligand. The Fas ligand may be provided to the recipient mammal by a variety of means, including by pump implantation or by transplantation of transgenic tissue expressing Fas ligand. Also provided is a method for diagnostic use of Fas ligand expression in improving transplantation success.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: June 2, 1998
    Assignee: University Technology Corporation
    Inventors: Donald Bellgrau, Richard C. Duke
  • Patent number: 5747340
    Abstract: This invention provides a vector for expression of a nucleic acid cassette in bronchial epithelial and vascular endothelial cells comprising a segment of the 5'-flanking region of the preproendothelin-1 gene, upstream from the transcription start site, the first exon of the preproendothelin-1 gene, and a nucleic acid cassette, wherein the nucleic acid cassette is located within the first exon, in sequential and positional relationship for expression of the nucleic acid cassette.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: May 5, 1998
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Dror Harats, Hiroki Kurihara, Paula Nanette Belloni, Charles Elliott Sigal
  • Patent number: 5684147
    Abstract: Disclosed are oligonucleotides having nucleotide sequences that hybridize to at least nucleotides 324 to 348 of a conserved gag region of the HIV-1 genome. These oligonucleotides have about 25 to 30 nucleotides linked by at least one non-phosphodiester internucleotide linkage which render them resistant to nuclease digestion. Also disclosed are therapeutic formulations containing such oligonucleotides and methods of inhibition HIV-1 proliferation and of treating HIV-1 infection in a mammal.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: November 4, 1997
    Assignee: Hybridon, Inc.
    Inventors: Sudhir Agrawal, Jin-Yang Tang
  • Patent number: 5675061
    Abstract: The present invention describes vectors and methods useful for the production of transgenic mollusks, in particular, transgenic abalone. The invention further describes transgenic mollusks having enhanced growth properties. In addition, the isolation and characterization of an abalone actin gene promoter region is disclosed.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 7, 1997
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dennis Alpha Powers, Lynna Madsen Hereford, deceased, Marta Gomez-Chiarri
  • Patent number: 5665581
    Abstract: This invention is directed to naturally virulent fungi which have cells transfected with the coding strand of a mycovirus RNA and which have reduced ability to cause disease in plants, and to compositions and methods of treatment of fungal disease with these fungi.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: September 9, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Baoshan Chen, Gil Ho Choi, Donald Lee Nuss
  • Patent number: 5650550
    Abstract: The present invention provides a mutant non-human vertebrate, in which all or some of the germ and somatic cells contain a mutation in at least one steroid hormone receptor allele, which mutation is introduced into the vertebrate, or an ancestor of the vertebrate, at an embryonic stage, and which mutation produces a phenotype in the vertebrate characterized by a deficit of functional steroid hormone receptors encoded by the allele. Also disclosed are related methods and constructs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 22, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kenneth S. Korach, Dennis B. Lubahn, Oliver Smithies
  • Patent number: 5629192
    Abstract: The present invention relates, in general, to methods for reducing cell tumorigenicity. More particularly, the present invention provides a method for reducing cell tumorigenicity comprising transfecting a tumor cell with an ETS1 gene, the tumor cell not endogenously expressing the ETS1 gene. In addition, the present invention provides a method for reducing cell tumorigenicity comprising contacting a tumor cell with a peptide expressed by an ETS1 gene, the tumor cell not endogenously expressing the ETSI gene. The methods of the present invention are particularly useful for reducing tumorigenicity in epithelial tumor cells.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: May 13, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Suzuki, Narayan K. Bhat, Takis S. Papas
  • Patent number: 5627159
    Abstract: A method is provided for enhancing transfection efficiency of eukaryotic cells comprising contacting said cells with a lipid aggregate comprising nucleic acid and a polycationic lipid composition in the presence of a polycationic compound and serum. The polycationic compound is preferably Polybrene.TM., and the lipid aggregate preferably comprises liposomes of nucleic acid and LipofectAMINE.TM..
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: May 6, 1997
    Assignee: Life Technologies, Inc.
    Inventors: PoJen Shih, Pamela Hawley-Nelson, Joel A. Jessee
  • Patent number: 5627059
    Abstract: Positive-negative selector (PNS) vectors are provided for modifying a target DNA sequence contained in the genome of a target cell capable of homologous recombination. The vector comprises a first DNA sequence which contains at least one sequence portion which is substantially homologous to a portion of a first region of a target DNA sequence. The vector also includes a second DNA sequence containing at least one sequence portion which is substantially homologous to another portion of a second region of a target DNA sequence. A third DNA sequence is positioned between the first and second DNA sequences and encodes a positive selection marker which when expressed is functional in the target cell in which the vector is used. A fourth DNA sequence encoding a negative selection marker, also functional in the target cell, is positioned 5' to the first or 3' to the second DNA sequence and is substantially incapable of homologous recombination with the target DNA sequence.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 6, 1997
    Assignee: University of Utah
    Inventors: Mario R. Capecchi, Kirk R. Thomas
  • Patent number: 5616565
    Abstract: Disclosed is a composition including an oligonucleotide complexed with a cyclodextrin. The oligonucleotide may be noncovalently associated with the cyclodextrin. Alternatively, the oligonucleotide may be covalently complexed with adamantane which is noncovalently associated with the cyclodextrin. Also disclosed are methods of enhancing the cellular uptake and intracellular concentration of oligonucleotides, methods of increasing the solubility of an oligonucleotide in a cell, and methods of treating a cell for viral infection or to prevent viral infection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 1, 1997
    Assignee: Hybridon, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao, Ivan Habus
  • Patent number: 5605890
    Abstract: Disclosed is a composition including an oligonucleotide complexed with a cyclodextrin. The oligonucleotide may be noncovalently associated with the cyclodextrin. Alternatively, the oligonucleotide may be covalently complexed with adamantane which is noncovalently associated with the cyclodextrin. Also disclosed are methods of enhancing the cellular uptake and intracellular concentration of oligonucleotides, methods of increasing the solubility of an oligonucleotide in a cell, and methods of treating a cell for viral infection or to prevent viral infection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 25, 1997
    Assignee: Hybridon, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao, Ivan Habus
  • Patent number: 5565187
    Abstract: A method is provided for studying capillary circulation utilizing intravital microscopy. The method comprises providing an intact living Salmonid or other Teleost alevin with yolk sac attached in a small water filled plastic bag or tube for immobilizing the fish fry. Thereafter there is injected into the yolk sac, a fluorescent dye complex and tracer FITC-DX (MW 150,000 daltons) and the absorption of the injected material into the systemic circulation of said living Salmonid or Teleost alevin tracked by means of fluorescent microscopy. The method can be used for carrying out toxicological pharmacological, physiological, embryological, oncological, pathological, etc. studies.
    Type: Grant
    Filed: July 10, 1995
    Date of Patent: October 15, 1996
    Inventors: Bashir Zikria, Suraya Zikria
  • Patent number: 5563055
    Abstract: A method for producing transgenic soybean plants is disclosed. The method employs conditions necessary for genotype-independent, Agrobacterium-mediated transformation of soybean explants and utilization of specialized medium to cause root induction.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: October 8, 1996
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Jeffrey A. Townsend, Laurie A. Thomas
  • Patent number: 5552390
    Abstract: A method of inhibiting tumor invasion and metastasis of cancer cells using antisense oligonucleotides is disclosed. Phosphorothioate oligos were developed which are complementary to proteolytic enzymes such as urokinase plasminogen activator which are associated with invasion. In vitro and in vivo experiments with these oligos demonstrated highly significant reduction in tumor invasion and metastasis of mammary carcinoma cells.
    Type: Grant
    Filed: December 9, 1993
    Date of Patent: September 3, 1996
    Assignee: The Board of Regents of The University of Nebraska
    Inventors: Eric M. Scholar, Patrick L. Iversen
  • Patent number: 5523222
    Abstract: The present invention provides a method of obtaining an organism which has been characterized as having cells containing exogenous genetic material which includes any sequence of DNA that can be distinguished as exogenous by known molecular biological analysis by insertion of genetic material into an animal's genetic makeup. The insertion of the genetic material is done by inserting DNA that has been complexed with molecules that allow the DNA to be inserted into the chromosomes when injected into the cytoplasm, perivitelline space, or placed in surrounding culture media to be taken up and incorporated into the genome. When the DNA is complexed into the polyelectrolyte molecules by electrostatic attraction, the electric charge of DNA of the complex is partially to substantially neutralized. The present method does not require the genetic material to be introduced into the embryo at a particular stage in development.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: June 4, 1996
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Raymond L. Page, William H. Velander, John L. Johnson
  • Patent number: 5489743
    Abstract: Transgenic mice and methods of preparing such mice are disclosed. The mice exhibit decreased platelet counts and/or megakaryocyte leukemia.
    Type: Grant
    Filed: January 19, 1993
    Date of Patent: February 6, 1996
    Assignee: Amgen Inc.
    Inventors: Murray O. Robinson, Pamela Hunt, Robert A. Bosselman
  • Patent number: 5486520
    Abstract: The present invention relates to the use of nucleoside analogues in the treatment of viral infections. More specifically it is concerned with the use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis, in particular hepatitis B.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: January 23, 1996
    Assignee: BioChemPharma, Inc.
    Inventors: Bernard Belleau, deceased, Nghe Nguyen-Ba
  • Patent number: 5484905
    Abstract: Described herein is a S receptor kinase gene (SRK), derived from the S locus in Brassica oleracea, having a extracellular domain highly similar to the secreted product of the S-locus glycoprotein gene.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: January 16, 1996
    Assignee: Cornell Research Foundation, Inc.
    Inventors: June B. Nasrallah, Mikhail E. Nasrallah, Joshua Stein
  • Patent number: 5387755
    Abstract: According to the invention, there is provided an inbred corn line, designated PHFA5. This invention thus relates to the plants and seeds of inbred corn line PHFA5 and to methods for producing a corn plant produced by crossing the inbred line PHFA5 with itself or with another corn plant. This invention further relates to hybrid corn seeds and plants produced by crossing the inbred line PHFA5 with another corn line or plant.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: February 7, 1995
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Roy Luedtke, Jr., Gerhard P. Weber